2. Search Result
Search Result
Results for "

Cushing syndrome

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16276
    Osilodrostat
    4 Publications Verification

    LCI699

    		 Mineralocorticoid Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) .
    Osilodrostat
  • HY-16276A
    Osilodrostat phosphate
    4 Publications Verification

    LCI699 phosphate

    		 Mineralocorticoid Receptor Cardiovascular Disease Cancer
    Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. Osilodrostat phosphate has blood pressure lowering ability. Osilodrostat phosphate can be used for research of Cushing syndrome (CS) .
    Osilodrostat phosphate
  • HY-109042
    Relacorilant

    CORT 125134

    		 Glucocorticoid Receptor Cardiovascular Disease Endocrinology
    Relacorilant is a potent, selective and orally bioavailable glucocorticoid receptor antagonist, with a Ki of 7.2 nM in HepG2 TAT assay, and also shows Kis of 12, 81.2, 210 nM for rat, human and monkey glucocorticoid receptor in cell-based assay, respectively. Relacorilant has the potential for Cushing’s syndrome treatment.
    Relacorilant
  • HY-B1232
    Metyrapone
    5 Publications Verification

    Su-4885

    		 Endogenous Metabolite Cytochrome P450 Autophagy Neurological Disease Metabolic Disease Endocrinology Cancer
    Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression .
    Metyrapone
  • HY-W740216
    N-Demethyl Mifepristone

    RU 42633

    		 Glucocorticoid Receptor Drug Metabolite Endocrinology
    N-Demethyl Mifepristone (RU 42633) is an active metabolite of Mifepristone (HY-13683). The affinities of N-Demethyl Mifepristone to the glucocorticoid receptor is 61% compared with 100% for Mifepristone .
    N-Demethyl Mifepristone
  • HY-B1232A
    Metyrapone Tartrate

    Su-4885 Tartrate

    		 Endogenous Metabolite Cytochrome P450 Autophagy mTOR Neurological Disease Endocrinology
    Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression .
    Metyrapone Tartrate
  • HY-B1232R
    Metyrapone (Standard)

    		Endogenous Metabolite Cytochrome P450 Autophagy Neurological Disease Metabolic Disease Endocrinology Cancer
    Metyrapone (Standard) is the analytical standard of Metyrapone. This product is intended for research and analytical applications. Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression .
    Metyrapone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: